SCHEMBL2421458

SCHEMBL2421458

OC(c1cccnc1)c1cncs1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.66
SMN1; SMN2 Q16637 2/20 0.58
GAA P10253 1/20 0.49
CYP17A1 P05093 1/20 0.49
LMNA P02545 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
CFTR P13569 1/20 0.43
SLC6A2 P23975 1/20 0.43
SLC6A4 P31645 1/20 0.43
SLC6A3 Q01959 1/20 0.43
GOPC Q9HD26 1/20 0.43
CYP19A1 P11511 2/20 0.39
CYP11B1 P15538 1/20 0.37
DYRK1A Q13627 2/20 0.37
DYRK2 Q92630 1/20 0.36
DYRK1B Q9Y463 1/20 0.36
BRD4 O60885 1/20 0.36
KCNN4 O15554 1/20 0.36
KCNA5 P22460 1/20 0.36
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8633394 0.84 SMN1; SMN2 (0.48) TSHRSMN1; SMN2L3MBTL1SLC6A2SLC6A4
SCHEMBL7246231 0.80 TSHR (0.67) TSHRSMN1; SMN2GAACYP17A1LMNA
SCHEMBL8309087 0.79 TSHR (1.00) TSHRSMN1; SMN2GAACYP17A1LMNA
SCHEMBL1242879 0.79 SMN1; SMN2 (0.87) TSHRSMN1; SMN2GAACYP17A1LMNA
SCHEMBL23931527 0.76 IDO1 (0.43) TSHRLMNASLC6A2SLC6A3KCNA5
SCHEMBL12199663 0.76 TSHR (0.42) TSHRSMN1; SMN2GAALMNAL3MBTL1
SCHEMBL23931525 0.76 IDO1 (0.43) TSHRLMNASLC6A2SLC6A3KCNA5
SCHEMBL30011604 0.76 IDO1 (0.43) TSHRLMNASLC6A2SLC6A3KCNA5
SCHEMBL31040275 0.74 TSHR (0.36) TSHRSMN1; SMN2CYP17A1CYP19A1CYP11B1
SCHEMBL2974022 0.74 SLC6A3 (0.45) TSHRSLC6A2SLC6A3CYP19A1CYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2374802-B1 KYNURENINE PRODUCTION INHIBITOR KYOWA HAKKO KIRIN CO LTD (JP) 2014-04-23 EP disclosed
US-8673908-B2 Kynurenine production inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2014-03-18 US disclosed
EP-2374802-A1 KYNURENINE PRODUCTION INHIBITOR Kyowa Hakko Kirin Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110237584-A1 KYNURENINE PRODUCTION INHIBITOR KYOWA KIRIN CO., LTD. (JP) 2011-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237584-A1 KYNURENINE PRODUCTION INHIBITOR KYNU, KMO, IDO1 TSHR 1897/4885SMN1; SMN2 4398/4885GAA 4031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.